Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer.
Click here for original story, Three-drug combination prolongs survival in men with metastatic, hormone-sensitive prostate cancer
Source: ScienceDaily